Andrew LaFrence - SurModics CFO, Vice President
| SRDX Stock | USD 33.33 7.64 29.74% |
President
Mr. Andrew D. C. LaFrence is no longer Chief Financial Officer, Vice President Finance and Information Systems of SurModics, Inc., effective May 25, 2018. He joined the Company in February 2013 as Vice President of Finance and Chief Financial Officer and was also named Vice President of Information Systems in August 2016. Prior to joining Surmodics, he served as Chief Financial Officer for CNS Therapeutics, which developed and marketed pharmaceuticals for sitespecific drug delivery to the central nervous system, from January 2011 to January 2013. Prior to joining CNS, Mr. LaFrence served as interim Chief Financial Officer of International Green Power from July 2010 to January 2011. Mr. LaFrence has over 30 years of financial and management experience including 26 years at KPMG LLP where, from 1996 to 2010, he was an audit partner focusing on supporting venturebacked, highgrowth medical technology, pharmaceutical, biotech and clean tech private and public companies
| Age | 53 |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
SurModics Management Efficiency
The company has return on total asset (ROA) of 0.0447 % which means that it generated a profit of $0.0447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0481 %, meaning that it created $0.0481 on every $100 dollars invested by stockholders. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.01 in 2024. Return On Capital Employed is likely to drop to 0.03 in 2024. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2024, whereas Total Assets are likely to drop slightly above 140.7 M in 2024.Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Sean Paolino | Bionano Genomics | N/A | |
| Mirasol Panlilio | Senseonics Holdings | 52 | |
| Massimo MBA | Jaguar Animal Health | 66 | |
| Mike Ward | Bionano Genomics | 46 | |
| Michael Gill | Senseonics Holdings | 47 | |
| Mukul Jain | Senseonics Holdings | 51 | |
Management Performance
| Return On Equity | 0.0481 | ||||
| Return On Asset | 0.0447 |
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Arens, VP of Corporate Devel. and Strategy | ||
| Thomas Greaney, Vice President - Operations, General Manager, SurModics Ireland | ||
| Charles Olson, Sr. VP and General Manager of Medical Device | ||
| Susan Knight, Independent Director | ||
| Gary Maharaj, CEO and President and Director | ||
| Andrew LaFrence, CFO, Vice President | ||
| Ronald Kalich, Independent Director | ||
| Lisa Heine, Director | ||
| John Manders, Corporate Controller and Principal Accounting Officer | ||
| Shawn McCormick, Independent Director | ||
| Gregg Sutton, Vice President - Research & Development | ||
| Teri Sides, Senior Vice President Chief Marketing Officer | ||
| John Benson, Independent Director | ||
| Jose Bedoya, Independent Director | ||
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | ||
| David Dantzker, Independent Director | ||
| Gordon Weber, General Legal | ||
| Teryl Sides, Senior Interventions | ||
| Bryan Phillips, Sr. VP of Legal and HR, General Counsel and Corporate Secretary |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0481 | ||||
| Return On Asset | 0.0447 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 364.42 M | ||||
| Shares Outstanding | 14.24 M | ||||
| Shares Owned By Insiders | 3.74 % | ||||
| Shares Owned By Institutions | 91.38 % | ||||
| Number Of Shares Shorted | 472.89 K | ||||
| Price To Earning | 69.21 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SurModics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SurModics' short interest history, or implied volatility extrapolated from SurModics options trading.
Currently Active Assets on Macroaxis
When determining whether SurModics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SurModics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Surmodics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Surmodics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SurModics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy SurModics Stock please use our How to Invest in SurModics guide.Note that the SurModics information on this page should be used as a complementary analysis to other SurModics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for SurModics Stock analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is SurModics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SurModics. If investors know SurModics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SurModics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.358 | Earnings Share 0.39 | Revenue Per Share 9.829 | Quarterly Revenue Growth 0.225 | Return On Assets 0.0447 |
The market value of SurModics is measured differently than its book value, which is the value of SurModics that is recorded on the company's balance sheet. Investors also form their own opinion of SurModics' value that differs from its market value or its book value, called intrinsic value, which is SurModics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SurModics' market value can be influenced by many factors that don't directly affect SurModics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SurModics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SurModics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SurModics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.